World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
87
Citations
32984
World Ranking
13518
National Ranking
1259

Overview

Graham R. Foster is affiliated with Queen Mary University of London in the United Kingdom. Their research primarily spans the field of Medicine, with significant contributions in the subfields of Epidemiology, Hepatology, Genetics, General Health Professions, and Infectious Diseases.

The scientist's work focuses extensively on viral hepatitis and liver-related diseases, with notable emphasis on Hepatitis C virus research, Liver Disease Diagnosis and Treatment, Hepatitis B Virus Studies, Liver Disease and Transplantation, Virus-based gene therapy research, Hepatitis Viruses Studies and Epidemiology, and Hemophilia Treatment and Research.

Frequent co-authors collaborating with Graham R. Foster include:

  • Beatrice Emmanouil
  • Saeed Hamid
  • Peter Vickerman
  • Mark Gillyon-Powell
  • Kosh Agarwal

The scientist has published prolifically in several journals, with the most frequent venues being:

  • Journal of Hepatology
  • Journal of Viral Hepatitis
  • bioRxiv (Cold Spring Harbor Laboratory)
  • Journal of Thrombosis and Haemostasis
  • Abstracts

Among the notable recent papers are:

  • "Estimated impact of the COVID-19 pandemic on cancer services and excess 1-year mortality in people with cancer and multimorbidity: near real-time data on cancer care, cancer deaths and a population-based cohort study," 2020, BMJ Open
  • "Estimating excess mortality in people with cancer and multimorbidity in the COVID-19 emergency," 2020, bioRxiv (Cold Spring Harbor Laboratory)
  • "Adjusted estimate of the prevalence of hepatitis delta virus in 25 countries and territories," 2023, Journal of Hepatology
  • "Increased burden of cardiovascular disease in people with liver disease: unequal geographical variations, risk factors and excess years of life lost," 2022, Journal of Translational Medicine
  • "Hepatitis D double reflex testing of all hepatitis B carriers in low-HBV- and high-HBV/HDV-prevalence countries," 2023, Journal of Hepatology

Best Publications

  • Ledipasvir and Sofosbuvir for Untreated HCV Genotype 1 Infection

    Nezam Afdhal;Stefan Zeuzem;Paul Kwo;Mario Chojkier

  • Telaprevir for retreatment of HCV infection.

    Stefan Zeuzem;Pietro Andreone;Stanislas Pol;Eric Lawitz

  • Interferons at age 50: past, current and future impact on biomedicine.

    Ernest C Borden;Ganes Sen;Gilles Uze;Robert H Silverman

  • Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection

    Graham R. Foster;Nezam Afdhal;Stuart K. Roberts;Norbert Bräu

  • Chronic hepatitis C virus infection causes a significant reduction in quality of life in the absence of cirrhosis

    G. R. Foster;R. D. Goldin;H. C. Thomas

  • Addressing liver disease in the UK: A blueprint for attaining excellence in health care and reducing premature mortality from lifestyle issues of excess consumption of alcohol, obesity, and viral hepatitis

    Roger Williams;Richard Aspinall;Mark Bellis;Ginette Camps-Walsh

  • Increase in primary liver cancer in the UK, 1979-94.

    Simon D Taylor-Robinson;Graham R Foster;Shona Arora;Sally Hargreaves

  • Hepatitis C Virus Treatment for Prevention Among People Who Inject Drugs: Modeling Treatment Scale-Up in the Age of Direct-Acting Antivirals

    Natasha K. Martin;Peter Vickerman;Jason Grebely;Margaret Hellard

  • Hepatitis C and cognitive impairment in a cohort of patients with mild liver disease.

    Daniel M. Forton;Daniel M. Forton;Howard C. Thomas;Christine A. Murphy;Joanna M. Allsop

  • Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis.

    Graham R. Foster;William L. Irving;Michelle C.M. Cheung;Alex J. Walker

  • MAIT cells are activated during human viral infections

    B van Wilgenburg;I Scherwitzl;E C Hutchinson;T Leng

  • Glecaprevir–Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection

    Stefan Zeuzem;Graham R Foster;Stanley Wang;Armen Asatryan

  • Outcomes after successful direct-acting antiviral therapy for patients with chronic hepatitis C and decompensated cirrhosis

    Michelle C.M. Cheung;Alex J. Walker;Benjamin E. Hudson;Suman Verma

  • Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial

    Ira M Jacobson;Gregory J Dore;Graham R Foster;Michael W Fried

  • Evidence for a cerebral effect of the hepatitis C virus.

    Daniel M Forton;Daniel M Forton;Joanna M Allsop;Janice Main;Graham R Foster

  • Combination of Tenofovir Disoproxil Fumarate and Peginterferon α-2a Increases Loss of Hepatitis B Surface Antigen in Patients With Chronic Hepatitis B

    Patrick Marcellin;Sang Hoon Ahn;Xiaoli Ma;Florin A. Caruntu

  • The way forward in HCV treatment — finding the right path

    Michael P. Manns;Graham R. Foster;Jürgen K. Rockstroh;Stefan Zeuzem

  • Dengue Virus Inhibits Alpha Interferon Signaling by Reducing STAT2 Expression

    Meleri Jones;Andrew Davidson;Linda Hibbert;Petra Gruenwald

  • Preserved T-Cell Function in Children and Young Adults With Immune-Tolerant Chronic Hepatitis B

    Patrick T.F. Kennedy;Elena Sandalova;Juandy Jo;Upkar Gill

  • Efficacy of 8 Weeks of Sofosbuvir, Velpatasvir, and Voxilaprevir in Patients With Chronic HCV Infection: 2 Phase 3 Randomized Trials

    Ira M. Jacobson;Ira M. Jacobson;Eric Lawitz;Edward J. Gane;Bernard E. Willems

Frequent Co-Authors

Stefan Zeuzem
Stefan Zeuzem Goethe University Frankfurt
Ira M. Jacobson
Ira M. Jacobson New York University
Zobair M. Younossi
Zobair M. Younossi Inova Health System
Stanislas Pol
Stanislas Pol Université Paris Cité
Gregory J. Dore
Gregory J. Dore University of New South Wales
Robert D. Goldin
Robert D. Goldin Imperial College London
Mark S. Sulkowski
Mark S. Sulkowski Johns Hopkins University School of Medicine
William L. Irving
William L. Irving University of Nottingham
Howard C. Thomas
Howard C. Thomas Imperial College London
Peter Ferenci
Peter Ferenci Medical University of Vienna

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring medicine in the USA doesn’t only mean becoming an MD. There’s a diverse array of professional and academic pathways you can pursue online. For example, if you want to enter the workforce quickly, fast track medical lpn programs online can prepare you for a career as a Licensed Practical Nurse in as little as one year.

If you’re already a registered nurse, consider advancing your career with bsn to np programs online. These programs offer specialized training and flexible learning formats, allowing you to become a Nurse Practitioner without pausing your current employment.

Interested in healthcare management? Affordable options exist for earning your online degree. Check out the cheapest online healthcare administration degree options to develop leadership and administrative skills. For those ready to advance further, understanding the cost of mha degree can help you plan for a master’s in healthcare administration.

Whether you’re seeking clinical or administrative roles, these online pathways offer flexibility, affordability, and the opportunity to make a real impact in healthcare.

Best Scientists Citing Graham R. Foster

Trending Scientists